TNF-Dependent Signaling Pathways in Liver Cancer: Promising Targets for Therapeutic Strategies?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TNF-Dependent Signaling Pathways in Liver Cancer: Promising Targets for Therapeutic Strategies?
Authors
Keywords
-
Journal
DIGESTIVE DISEASES
Volume 30, Issue 5, Pages 500-507
Publisher
S. Karger AG
Online
2012-10-30
DOI
10.1159/000341700
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma?
- (2015) Oncotarget
- Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?
- (2011) Etsuko Hashimoto et al. HEPATOLOGY RESEARCH
- Role of TNF superfamily ligands in innate immunity
- (2011) Nikola L. Vujanovic IMMUNOLOGIC RESEARCH
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
- (2011) Tom Luedde et al. Nature Reviews Gastroenterology & Hepatology
- Molecularly targeted therapy in hepatocellular carcinoma
- (2010) Hung Huynh BIOCHEMICAL PHARMACOLOGY
- TAK1 Suppresses a NEMO-Dependent but NF-κB-Independent Pathway to Liver Cancer
- (2010) Kira Bettermann et al. CANCER CELL
- Hepatitis B virus DNA levels and outcomes in chronic hepatitis B
- (2010) Chien-Jen Chen et al. HEPATOLOGY
- The Etiology of Hepatocellular Carcinoma and Consequences for Treatment
- (2010) A. J. Sanyal et al. ONCOLOGIST
- Epidemiology of Hepatocellular Carcinoma
- (2010) Morris Sherman ONCOLOGY
- Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis
- (2010) Morris Sherman SEMINARS IN LIVER DISEASE
- Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
- (2010) Alejandro Forner et al. SEMINARS IN LIVER DISEASE
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma
- (2009) Johannes Haybaeck et al. CANCER CELL
- Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance
- (2009) Giuseppe Cabibbo et al. DIGESTIVE DISEASES
- TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes
- (2009) Michael Karin et al. IMMUNOLOGICAL REVIEWS
- The IκB kinase – a bridge between inflammation and cancer
- (2008) Michael Karin CELL RESEARCH
- p38α MAPK inhibits JNK activation and collaborates with IκB kinase 2 to prevent endotoxin-induced liver failure
- (2008) Jan Heinrichsdorff et al. EMBO REPORTS
- Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease
- (2008) Anna S. Lok et al. GASTROENTEROLOGY
- Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
- (2008) Vincenzo Mazzaferro et al. LANCET ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Is NF-κB a good target for cancer therapy? Hopes and pitfalls
- (2008) Véronique Baud et al. NATURE REVIEWS DRUG DISCOVERY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
- (2008) Yujin Hoshida et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatic NF- B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis
- (2008) F. T. Wunderlich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More